Obeticholic acid may reduce the risk of negative outcomes in PBC
Treatment of primary biliary cholangitis (PBC) with obeticholic acid may reduce negative outcomes in the disease, according to a study.
News
-
-
CymaBay submits New Drug Application for PBC treatment
Seeking a Priority Review designation, CymaBay anticipates that the FDA will conclude its evaluation of the PBC treatment within six months.
-
Study shows high and variable prevalence of PBC in the US
The prevalence of primary biliary cholangitis (PBC) in the U.S. may be high and variable between regions, according to a recent study.
-
High blood fat in PBC may not affect blood vessels and liver health
High blood levels of fats such as triglycerides and cholesterol in patients with PBC may not increase their risk for cardiovascular disease.
- Living with brain fog associated with PBC
- Some of my fellow PBC patients report trouble finding ursodiol
- The reality of chronic fatigue and PBC
From the
PBC Ambassador
PBC Ambassador
Learn more about PBC
Sign up for the latest news, perspectives, and information about PBC.
